Hypothesis: In aging hematopoietic stem cells (HSCs), accumulation of copy‑number variants (CNVs) activates the ATM‑Chk2 DNA‑damage signaling cascade, leading to phosphorylation and stabilization of the transcriptional repressor KLF4. KLF4 binds the promoter of NAMPT, the rate‑limiting enzyme of the NAD+ salvage pathway, and suppresses its transcription. Reduced NAMPT lowers intracellular NAD+, which in turn limits PARP‑1 activity and SIRT1‑dependent deacetylation, imposing a metabolic checkpoint that curtails the proliferative advantage of genomically unstable clones. This NAD+ downgrade functions as a cell‑intrinsic tumor‑suppressive mechanism, trading short‑term regenerative capacity for long‑term cancer avoidance.

Predictions: (1) HSCs harboring age‑associated CNVs will show higher phospho‑ATM/Chk2, increased nuclear KLF4, and lower NAMPT mRNA and protein compared with CNV‑negative counterparts. (2) Forced expression of NAMPT in CNV‑positive HSCs will restore NAD+ levels, enhance PARP‑mediated DNA repair, and accelerate clonal expansion in competitive transplantation assays, without increasing apoptosis. (3) Knock‑down of KLF4 in aged HSCs will rescue NAMPT expression and NAD+ levels, but will also increase the incidence of myeloid malignancies in murine models. (4) Pharmacologic inhibition of ATM or Chk2 in aged mice will diminish KLF4 activation, elevate NAD+ salvage, and exacerbate clonal hematopoiesis.

Experimental approach: Isolate Lin‑ ⁻ Sca‑1⁺ c‑Kit⁺ (LSK) cells from young (3 mo) and old (24 mo) mice, sort them by single‑cell CNV profiling using low‑pass whole‑genome sequencing. Quantify phospho‑ATM, phospho‑Chk2, KLF4, NAMPT, and NAD+ levels by flow cytometry, western blot, and enzymatic assay. Perform gain‑ and loss‑of‑function studies using retroviral NAMPT overexpression or CRISPR‑mediated KLF4 knockout in sorted LSK cells, then assess competitive repopulation, clonal dynamics (barcode sequencing), and leukemic transformation over 6 months. Parallel analyses in human cord blood CD34⁺ cells cultured with low‑dose aphidicolin to induce CNVs will test conservation of the ATM‑Chk2‑KLF4‑NAMPT axis.

Falsifiability: If CNV‑positive HSCs do not exhibit elevated KLF4 activity or reduced NAMPT, or if modulating NAMPT/KLF4 fails to alter NAD+ levels and clonal outcomes as predicted, the hypothesis would be refuted. Conversely, confirmation would support the notion that age‑related NAD+ decline is not merely a passive deterioration but an active, genomically triggered metabolic restraint that balances tissue maintenance against cancer risk.